PMID- 25857825
OWN - NLM
STAT- MEDLINE
DCOM- 20160406
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 28
IP  - 7
DP  - 2015 Jul
TI  - ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.
PG  - 904-12
LID - 10.1038/modpathol.2015.49 [doi]
AB  - Epithelioid benign fibrous histiocytoma, also known as 'epithelioid cell 
      histiocytoma,' has traditionally been considered a morphologic variant of 
      cutaneous fibrous histiocytoma (dermatofibroma). In addition to its 
      characteristic epithelioid cytomorphology, several phenotypic differences suggest 
      that epithelioid fibrous histiocytoma may differ biologically from other 
      variants. Recently, ALK rearrangement was described in two cases of epithelioid 
      fibrous histiocytoma and separately in two cases reported as 'atypical' fibrous 
      histiocytoma (with epithelioid features), with corresponding ALK expression 
      detectable by immunohistochemistry. The goals of this study were to determine the 
      frequency of ALK expression by immunohistochemistry in epithelioid fibrous 
      histiocytoma, to determine its value for the diagnosis of epithelioid fibrous 
      histiocytoma among variants and other histologic mimics, and to evaluate ALK gene 
      rearrangement in epithelioid fibrous histiocytoma. ALK protein expression was 
      evaluated in whole tissue sections from 33 epithelioid fibrous histiocytomas, 41 
      other cases of fibrous histiocytoma (11 conventional and 10 each cellular, 
      atypical, and aneurysmal types), 10 cutaneous syncytial myoepitheliomas, and 5 
      atypical fibroxanthomas, using a mouse anti-ALK monoclonal antibody. Fluorescence 
      in situ hybridization (FISH) was performed using break-apart probes. In total, 
      29/33 (88%) cases of epithelioid fibrous histiocytoma showed diffuse cytoplasmic 
      ALK expression. Staining was moderate to strong in intensity in all cases except 
      one, which showed diffuse weak expression. All other tumor types were negative 
      for ALK expression. FISH demonstrated ALK rearrangement in all ALK-immunoreactive 
      cases evaluated (n=13), and not in one ALK expression-negative epithelioid 
      fibrous histiocytoma successfully examined. In conclusion, the majority of 
      epithelioid fibrous histiocytomas demonstrate ALK expression and ALK gene 
      rearrangement. ALK expression is not seen in other variants of fibrous 
      histiocytoma, providing a useful diagnostic tool to distinguish epithelioid 
      fibrous histiocytoma from most histologic mimics. The expression of ALK suggests 
      that epithelioid fibrous histiocytoma is a biologically distinct tumor type, 
      unrelated to conventional fibrous histiocytoma and histologic variants.
FAU - Doyle, Leona A
AU  - Doyle LA
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Marino-Enriquez, Adrian
AU  - Marino-Enriquez A
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Fletcher, Christopher D M
AU  - Fletcher CD
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Hornick, Jason L
AU  - Hornick JL
AD  - Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20150410
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Alk protein, mouse)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Diagnosis, Differential
MH  - Epithelioid Cells/*metabolism/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - *Gene Rearrangement
MH  - Histiocytoma, Benign Fibrous/*diagnosis/genetics/metabolism/pathology
MH  - Humans
MH  - Receptor Protein-Tyrosine Kinases/*genetics/metabolism
MH  - Skin Neoplasms/*diagnosis/genetics/metabolism/pathology
EDAT- 2015/04/11 06:00
MHDA- 2016/04/07 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/01/15 00:00 [received]
PHST- 2015/03/06 00:00 [revised]
PHST- 2015/03/07 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/04/07 06:00 [medline]
AID - S0893-3952(22)01399-0 [pii]
AID - 10.1038/modpathol.2015.49 [doi]
PST - ppublish
SO  - Mod Pathol. 2015 Jul;28(7):904-12. doi: 10.1038/modpathol.2015.49. Epub 2015 Apr 
      10.